Back to Search
Start Over
Atypical patterns of response and progression in the era of immunotherapy combinations
- Source :
- Future oncology (London, England). 16(23)
- Publication Year :
- 2020
-
Abstract
- In the immunoncology era, an acceleration of tumor growth upon immune checkpoint inhibitors (ICI), defined as hyperprogressive disease (HPD) has been observed across different cancers. Although in non-small-cell lung cancer, most of the available evidence regarding HPD has been reported for patients treated with single agent PD-1 and PD-L1 inhibitors, in retrospective series a variable proportion of patients receiving ICI combinations also experienced HPD. Similarly, the shape of survival curves and the progression rates in clinical trials testing combinations of PD-1/PD-L1 inhibitors and anti-CTLA-4 agents suggest the occurrence of HPD. Few data are available regarding pseudoprogression upon ICI combinations. However, considering that pseudoprogression has been reported for anti-PD-1/PD-L1 agents and for CTLA-4 inhibitors separately, it is likely that it may occur also upon combinations of these two classes of drugs.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Immune checkpoint inhibitors
medicine.medical_treatment
Disease
03 medical and health sciences
0302 clinical medicine
Internal medicine
Neoplasms
medicine
Humans
Tumor growth
Lung cancer
Pseudoprogression
Immune Checkpoint Inhibitors
Survival analysis
Response Evaluation Criteria in Solid Tumors
Clinical Trials as Topic
business.industry
General Medicine
Immunotherapy
medicine.disease
Clinical trial
Survival Rate
030104 developmental biology
Treatment Outcome
030220 oncology & carcinogenesis
Disease Progression
business
Subjects
Details
- ISSN :
- 17448301
- Volume :
- 16
- Issue :
- 23
- Database :
- OpenAIRE
- Journal :
- Future oncology (London, England)
- Accession number :
- edsair.doi.dedup.....85efc63dd2aa76eb08db731953d04f38